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Abstract ????
High blood pressure is a major risk factor for cardiovascular disease and premature death. ????
However, there is limited knowledge on specific causal genes and pathways. To better ????
understand the genetics of blood pressure we genotyped 242,296 rare, low-frequency and ????
common genetic variants in up to ~192,000 individuals, and used ~155,063 samples for ????
independent replication. We identified 31 novel blood pressure or hypertension associated ????
genetic regions in the general population, including three rare missense variants in RBM47, ????
COL21A1 and RRAS with larger effects (>1.5mmHg/allele) than common variants. Multiple ????
rare, nonsense and missense variant associations were found in A2ML1 and a low-frequency ????
nonsense variant in ENPEP was identified. Our data extend the spectrum of allelic variation ????
underlying blood pressure traits and hypertension, provide new insights into the ????
pathophysiology of hypertension, and indicate new targets for clinical intervention.  ????
  ????
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High blood pressure (BP) or hypertension is a highly prevalent chronic disorder. It is ????
estimated to be responsible for a larger proportion of global disease burden and premature ????
mortality than any other disease risk factor1. Elevated systolic and/or diastolic BP increases ????
the risk of several cardiovascular disorders including stroke, coronary heart disease (CHD), ????
heart failure, peripheral arterial disease and abdominal aortic aneurysms2. BP is a complex, ????
heritable, polygenic phenotype for which genome-wide association studies (GWAS) have ????
identified over 67 genetic regions associated with BP and/or hypertension to date3-11. These ????
variants are common (minor allele frequency, MAF > 0.05), mostly map to intronic or ????
intergenic regions, with the causal alleles and genes not readily identified due to linkage ????
disequilibrium (LD) 4,5, and explain only ~2% of trait variance ??. Low-frequency (0.01 < ????
MAF < 0.05) and rare (MAF ≤ 0.01) single nucleotide variants (SNVs), predominantly ????
unexplored by GWAS may have larger phenotypic effects than common SNVs13, and may ????
help to explain the missing heritability, and identify causative genes as demonstrated ????
previously??.  ????
To identify novel coding variants and loci influencing BP traits and hypertension we ????
performed the largest meta-analysis to date that included a total of ~350,000 individuals, ????
directly genotyped with the Exome chip. The Exome chip contains ~240,000 mostly rare and ????
low-frequency variants (Methods). A single-variant discovery analysis was performed, and ????
candidate SNVs were taken forward for validation using independent replication samples. ????
Gene-based tests were used to identify BP associated genes harboring multiple rare variant ????
associations.  We next assessed whether the newly identified BP associated SNVs were ????
associated with expression levels of nearby genes, and tested these variants in aggregate for a ????
causal association of BP with other cardiovascular traits and risk factors. Our findings ????
highlight the contribution of rare variants in the aetiology of blood pressure in the general ????
population, and provide new insights into the pathophysiology of hypertension.   ????
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 ????
Results ????
Discovery of single variant BP associations  ????
We genotyped 192,763 individuals from 51 studies, and assessed association of 242,296 ????
SNVs with diastolic BP (DBP), systolic BP (SBP), pulse pressure (PP) and hypertension ????
(HTN; Supplementary Tables 1, 2 and 3; Methods; Supplementary Information). An ????
overview of the SNV discovery study design is given in Figure 1.  A fixed effects meta-????
analysis for each trait was performed using study-level association summary statistics from i) ????
samples of European (EUR) ancestry (up to 165,276 individuals), and ii) a trans-ethnic meta-????
analysis of the EUR and additional South Asian (SAS) ancestry samples (EUR_SAS; up to ????
192,763 individuals). Two analyses of DBP, SBP and PP were performed, one in which the ????
trait was inverse normal transformed and a second in which the raw phenotype was analysed. ????
Both sets of results were consistent (Methods), therefore to minimise sensitivity to deviations ????
from normality in the analysis of rare variants, the results from the analyses of the ????
transformed traits were used for discovery. Strong correlations between the BP traits were ????
observed across studies (Methods), hence no adjustment of significance thresholds for ????
independent trait testing was applied.  ????
The discovery meta-analyses identified 50 genomic regions with genome-wide significant ????
(GWS) evidence of association with at least one of the four BP traits tested (P<5x10-8; ????
Supplementary Table 4). There were 45 regions associated in the EUR_SAS samples, of ????
which 13 were novel (Figure 2). An additional five regions were GWS in the EUR only meta-????
analyses of which two were novel (Supplementary Figure 1).  In total, 16 genomic regions ????
were identified that were GWS for at least one BP trait that have not been previously ????
reported. ????
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Replication of single variant BP associations  ????
Next we sought support for our findings, in an independent replication dataset comprising of ????
18 studies, 16 of which were from the Cohorts for Heart and Aging Research in Genomic ????
Epidemiology+ (CHARGE+) consortium (Figure 1; Supplementary Information; Liu et al. ????
Nature Genetics, submitted).  Variants were selected for replication first using the larger ????
(transformed) EUR_SAS data, with additional variants from the (transformed) EUR data also ????
selected. SNVs were selected if they mapped outside of known BP genomic regions and had ????
MAF ≥ 0.05 and P < 1x10-5 or MAF < 0.05 and P < 1x10-4 with at least one BP trait, i.e. ????
choosing a lower significance threshold for the selection of rare variants (full details of the ????
selection criteria are provided in the Methods). In total 81 candidate SNVs were selected for ????
replication (Supplementary Table 5). Eighty variants were selected from EUR_SAS ????
(transformed) results and one SNV at the ZNF101 locus from the EUR (transformed) ????
analyses. The results for EUR_SAS and EUR were consistent (association statistics were ????
correlated, ρ=0.9 across ancestries for each of the traits). Of the 81 variants, 30 SNVs were ????
selected for association with DBP as the primary trait, 26 for SBP, 19 for PP and 6 for HTN, ????
with the primary trait defined as the BP trait with the smallest association P-value in the ????
EUR-SAS discovery analyses. ????
Meta-analyses were performed on results from analyses of untransformed DBP, SBP, PP and ????
HTN (as only results of untransformed traits were available from CHARGE+) in (i) up to ????
125,713 individuals of EUR descent, and (ii) up to 155,063 individuals of multiple ethnicities ????
(4,632 of Hispanic descent, 22,077 of African American descent, 2,641 SAS samples with the ????
remainder EUR; Figure 1; Supplementary Information). Given that a large proportion of the ????
ancestries in the trans-ethnic meta-analyses were not included in our discovery samples, we ????
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used the EUR meta-analyses as the main data set for replication, but we also report any ????
additional associations identified within the larger trans-ethnic dataset. ????
Novel BP-SNV associations were identified based on two criteria (Figure 1; Methods). ????
Firstly, replication of the primary BP trait-SNV association was sought at a Bonferroni ????
adjusted P-value threshold in the replication data (P≤6.17x10-4, assuming α=0.05 for 81 ????
SNVs tested and same direction of effect; Methods) without the need for GWS. Secondly, ????
meta-analyses of discovery and replication results across all four (untransformed) BP traits ????
were performed to assess the overall level of support across all samples for the 81 candidate ????
SNVs; those BP-SNV associations that were GWS (with statistical support in the replication ????
studies; P<0.05 and the same direction of effect) were also declared as novel. ????
 ????
Seventeen SNV-BP associations formally replicated with concordant direction of effect at a ????
Bonferroni adjusted significance level for the primary trait. Fourteen were in the EUR meta-????
analyses, and amongst these was a rare non-synonymous (ns) SNV mapping to COL21A1 ????
(Table 1a, Supplementary Table 6). Three associations were in the trans-ethnic meta-????
analyses, these included two rare nsSNVs in RBM47 and RRAS (Table 1a, Supplementary ????
Table 7; Methods).  ????
  ????
In addition to the 17 SNV-BP trait associations that formally replicated, we identified 13 ????
further SNV-associations that were GWS in the combined (discovery and replication) meta-????
analyses. Ten of these were GWS in the combined EUR analyses, (Table 1b; Supplementary ????
Tables 6 and 8a), and three were GWS in the combined trans-ethnic meta-analyses (Table 1b; ????
Supplementary Tables 7 and 8b). ????
 ????
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This gives a total of 30 novel SNV-BP associations (15 SNV-DBP, 9 SNV-SBP and 6 SNV-????
PP; Tables 1a and 1b; Supplementary Figures 2 and 3). Five of the SNVs were GWS with ????
more than one BP trait (Figure 3: Tables 1a and 1b; Supplementary Table 8). Four loci ????
(CERS5, TBX2, RGL3 and OBFC1) had GWS associations with HTN in addition to GWS ????
associations with DBP and SBP. The PRKAG1 locus had GWS associations with both SBP ????
and PP. ????
 ????
Conditional analyses were performed to identify secondary signals of association within the ????
novel BP loci. The RAREMETALWORKER (RMW) package (Methods) ?? allows ????
conditional analyses to be performed using summary level data. Hence, analyses of the ????
transformed primary traits and HTN were re-run in RMW across the discovery studies ????
(Figure 4).  The results of the RMW single variant tests were consistent with the initial ????
discovery analyses (Methods). Given that the RMW analyses are based on our discovery ????
samples, the larger EUR-SAS data was used as the main analysis to increase power, but we ????
also report any additional associations with evidence in EUR.  ????
 ????
We identified secondary independent signals of association in four loci, PREX1, PRKAG1 ????
and RRP1B within the EUR_SAS analyses and COL21A1 in the EUR analyses ????
(Pconditional<1x10-4; Methods; Supplementary Tables 9 and 10). Three independent association ????
signals were identified in the MYH6 locus in the EUR_SAS analyses (Supplementary Table ????
11).  ????
Gene-based BP associations  ????
To improve statistical power to detect associations in genes harbouring rare variants, ????
analytical methods that combine effects of variants across a gene into a single test have been ????
devised and are implemented in the RMW package 15. We applied the gene-based sequence ????
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kernel association test (SKAT) 16  and Burden tests ???to the RMW dataset (MAF < 0.05 or ????
MAF < 0.01; Figure 4; Methods). One previously unidentified BP gene (A2ML1) was ????
associated with HTN (P= 7.73x10-7) in the EUR_SAS studies and also in EUR studies (Table ????
2; Bonferroni-corrected threshold of significance P <2.8x10-6, after adjusting for 17,996 ????
genes tested, Methods). The gene showed residual association with the primary BP trait after ????
conditioning on the most associated SNV in the gene (Pconditional =5.00x10-4; Table 2), ????
suggesting that the association is due to multiple rare variants in the gene. One nonsense ????
variant (rs199651558, R893X, MAF=3.5x10-4) was observed, and there were multiple ????
missense variants (Figure 5).  A2ML1 encodes alpha-2-macroglobulin-like 1 protein, and is a ????
member of the alpha macroglobulin superfamily, which comprises protease inhibitors ????
targeting a wide range of substrates. Mutations in this gene are associated with a disorder ????
clinically related to Noonan syndrome, a developmental disorder which involves cardiac ????
abnormalities18. We sought replication in the CHARGE+ studies for this gene, however there ????
was no evidence of association with HTN (P= 0.45). Given the very low frequencies of the ????
variants involved, however, studies in which the variants are polymorphic will be required to ????
replicate the association with HTN. The DBH gene was found to be associated with DBP ????
using the SKAT test (P=2.88x10-6). However, this was not due to multiple rare variants as the ????
association was driven by rs77273740 (Supplementary Table 5) and the SNV was not ????
validated in the replication samples. ????
 ????
Rare and common variant associations in established BP loci ????
Of the 67 established BP loci, 35 loci were on the Exome chip (N=43 SNVs or close proxies ????
r2>0.7). All 43 SNVs had at least nominal evidence of association with BP in our discovery ????
samples (P< 0.01; Supplementary Table 13). We also assessed if any of the established BP ????
loci contained coding variants that are associated with BP traits and in LD (r2>0.2) with the ????
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known BP variants on the Exome chip (Supplementary Table 13), using the 1000G phase 3 ????
release for LD annotation. Focusing on SNVs that were GWS for any BP trait from our ????
transformed discovery data for either ancestry, there were 25 coding variants, of which 6 ????
were predicted to be damaging at loci labelled CDC25A, SLC39A8, HFE, ULK4, ST7L-????
CAPZA1-MOV10 and CYP1A1-ULK3. Three of these are published variants at loci labelled ????
SLC39A8, HFE and ST7-CAPZA1-MOV10. At CYP1A1-ULK3, the coding variant was in ????
moderate LD with the reported variant, but was less significantly associated with DBP in our ????
EUR_SAS dataset (P=2.24x10-8 compared to P=1.68x10-15 for the published variant). At the ????
ULK4 locus the predicted damaging coding variant had similar association as the published ????
coding variant (predicted to be benign), and prior work has already indicated several ????
associated nsSNVs in strong LD in ULK4 ??. The nsSNV within the CDC25A locus ????
(rs11718350 in SPINK8) had similar association with DBP as the intergenic published SNV ????
in our EUR_SAS dataset (P=2.00x10-8 compared to P=2.27x10-8 for the published variant). ????
Overall at least 5 of the known loci are consistent with having a coding causal variant. ????
Gene-based SKAT tests of all genes that map within 1 Mb of a previously reported SNV ????
association (Supplementary Table 14), indicated no genes with multiple rare or low-????
frequency variant associations. Single variant conditional analyses showed that rs33966350, a ????
rare nonsense variant in ENPEP (MAF=0.01) was associated with SBP (Pconditional = 1.61x10-????
5) in the EUR_SAS samples (Supplementary Tables 14 and 15; Methods) independently of ????
the known SNV (rs6825911). ENPEP encodes aminopeptidase A (APA) an enzyme of the ????
renin-angiotensin-aldosterone system (RAAS) that converts angiotensin II (AngII) to AngIII.  ????
There were no other established loci with convincing low-frequency or rare SNV associations ????
in the EUR_SAS samples. However, HOXC4, had evidence of a second independent signal ????
with a rare missense SNV in EUR samples (rs78731604; MAF = 0.005, Pconditional=?5.76x10-5; ????
Supplementary Table 15).  The secondary signal in the HOXC4 region, mapped to ????
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CALCOCO1, ~300kb from the known SNV. The gene association (MAF≤0.01, P=2.37x10-5) ????
was below the required significance threshold and attributable to rs78731604, which is not ????
predicted to have detrimental effects on protein structure. Therefore replication of this ????
association is required. Three loci (ST7L-CAPZA1-MOV10, FIGN-GRB14, and TBX5-TBX3) ????
had evidence of a second independent signal in the region in EUR_SAS samples with a ????
common variant (Pconditional<1x10-4; Supplementary Table 15) that has not been previously ????
reported.   ????
Having identified 30 novel loci associated with BP traits, as well as additional new ????
independent SNVs at four novel loci and five known loci, we calculated the percent of the ????
trait variance explained (Methods). This was 2.08%/2.11%/1.15% for SBP/DBP/PP for the ????
43 previously reported BP-SNVs covered in our dataset, increasing to 3.38%/3.41%/2.08% ????
respectively with the inclusion of the 30 lead SNVs from novel loci, plus new independent ????
SNV-BP associations identified from novel and known loci. ????
 ????
Effect of BP SNVs on cardiovascular traits & risk factors ????
Amongst our novel BP-SNV associations, some have previously been reported to be ????
associated with other cardiovascular traits and risk factors (Supplementary Table 16); these ????
include coronary heart disease (CHD: PHACTR1, ABO)??????, QT interval (RNF207)???, heart ????
rate (MYH6)???, and cholesterol levels (2q36.3, ABO, ZNF101)???. ????
To test the impact of BP variants on cardiovascular endpoints and risk factors we created ????
three weighted genetic risk scores (GRS) according to DBP/SBP/PP based on the newly ????
identified and previously published BP variants (up to N=125; Methods). The GRS models ????
were used to test the causal effect of BP on the following traits: ischemic stroke (including ????
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the subtypes, cardiometabolic, large and small vessel ??), CHD, heart failure, ???left ventricular ????
mass ??, left ventricular wall thickness ??, high-density lipoprotein cholesterol (HDL-c), low-????
density lipoprotein (LDL-c), triglycerides, total cholesterol, body mass index (BMI), waist-????
hip ratio adjusted BMI, height and estimated glomerular filtration rate (eGFR) (Methods). As ????
expected, BP was positively associated with increased CHD risk (OR [95% CI]=1.62 [1.28-????
2.05] per 10mmHg increase in DBP, P=5.99x10-5; 1.39 [1.22-1.59] per 10mmHg increase in ????
SBP, P=6.07×10-7; 1.70 [1.34-2.16], per 10mmHg increase in PP, P=1.20x10-5; Table 3), and ????
increased risk of ischemic stroke (OR [95% CI]=1.93 [1.47-2.55] per 10mmHg increase in ????
DBP, P=2.81×10-6; 1.57 [1.35-1.84] per 10mmHg increase in SBP, P=1.16×10-8; 2.12 [1.58-????
2.84], per 10mmHg increase in PP, P=5.35x10-7). The positive association with ischemic ????
stroke was primarily due to large vessel stroke (Table 3).  DBP and SBP were also positively ????
associated with left ventricular mass (9.57 [3.98-15.17] gram increase per 10mmHg increase ????
in DBP, P=8.02x10-4 and 5.13 [1.77-8.48] gram increase per 10mmHg increase in SBP, ????
P=0.0027) and left ventricular wall thickness (0.10cm [0.06-0.13] increase per 10mmHg ????
increase in DBP, P=1.88x10-8 and 0.05cm [0.03-0.07] increase per 10mmHg increase in SBP, ????
P=5.52x10-6, Table 3). There was no convincing evidence to support the BP associated ????
variants having an effect on lipid levels (P>0.1), BMI (P>0.005), waist hip ratio adjusted ????
BMI (P>0.1), height (P>0.06), eGFR (P>0.02) or heart failure (P>0.04). The causal ????
associations with CHD, stroke, and left ventricular measures augment the results from a ????
previous association analysis using 29 BP variants ??. Our data strongly support the previous ????
observations of no causal relationship between BP and eGFR. Lack of evidence of a BP ????
effect with heart failure may only be due to lack of power, as the association was in the ????
expected direction.  ????
 ????
Potential functional variants at BP loci and candidate genes ????
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Twenty-six of our newly discovered BP associated SNVs had MAF > 0.05 and therefore due ????
to extensive LD with other SNVs not genotyped on the Exome array, identifying the causal ????
genes requires additional information. If a SNV is associated with increased or decreased ????
expression of a particular gene, i.e. it is an expression quantitative trait locus (eQTL) this ????
suggests the gene on which the SNV acts could be in the causal pathway. To help identify ????
potential candidate causal genes in the novel BP loci (Supplementary Table 9), expression ????
quantitative trait loci (eQTL) information from publicly available databases were investigated ????
across a range of tissues and cells (MuTHER for LCL, adipose and skin and GTEx for nine ????
tissues including the heart and tibial artery; Methods). ????
The DBP increasing allele of the nsSNV, rs7302981-A, was associated with increased ????
expression of CERS5 in four tissues: LCLs (PMuTHER=3.13x10-72) skin (PMuTHER=2.40x10-58) ????
adipose (PMuTHER=2.87x10-54) and nerve (PGTEx=4.5x10-12) (Supplementary Figure 4). ????
Additional testing (Methods) provided no evidence against colocalisation of the eQTL and ????
DBP association signals, implicating CERS5 as a candidate causal gene for this DBP locus. ????
CERS5 (LAG1 homolog, ceramide synthase 5) is involved in the synthesis of ceramide, a ????
lipid molecule that is involved in a several cellular signaling pathways. CERS5 knockdown ????
has been shown to reduce cardiomyocyte hypertrophy in mouse models??. However, it is ????
unclear whether the blood pressure raising effects at this locus are the cause or result of any ????
potential effects on cardiac hypertrophy. Future studies investigating this locus in relation to ????
parameters of cardiac hypertrophy and function (e.g. ventricular wall thickness) should help ????
address this question. ????
The DBP raising allele of the nsSNV (rs867186-A) was associated with increased expression ????
of PROCR in adipose tissue (PMuTHER=3.24x10-15) and skin (PMuTHER=1.01x10-11) ????
(Supplementary Figure 4). There was no evidence against colocalisation of the eQTL and ????
DBP association thus supporting PROCR as a candidate causal gene. PROCR encodes the ????
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Endothelial Protein C receptor, a serine protease involved in the blood coagulation pathway, ????
and rs867186 has previously been associated with coagulation and haematological factors.??????????
The PP decreasing allele of the nsSNV, rs10407022-T, which is predicted to have detrimental ????
effects on protein structure (Methods) was associated with increased expression of AMH in ????
muscle (PGTEx=9.95x10-15), thyroid (PGTEx=8.54x10-7), nerve (PGTEx=7.15x10-8), tibial artery ????
(PGTEx=6.46x10-9), adipose (PGTEx=4.69x10-7), and skin (PGTEx=5.88x10-8) (Supplementary ????
Figure 4). There was no evidence against colocalisation of the eQTL and PP association, ????
which supports AMH as a candidate causal gene for PP. Low AMH protein levels have been ????
previously associated with hypertensive status in women with the protein acting as a marker ????
of ovarian reserve ??. The intergenic SBP raising allele of rs4728142-A was associated with ????
reduced expression of IRF5 in skin (PMuTHER=5.24x10-31) and LCLs (PMuTHER=1.39x10-34), ????
whole blood (PGTEx=3.12x10-7) and tibial artery (PGTEx=1.71x10-7). ?????
 ????
Three novel rare nsSNVs were identified that map to RBM47, RRAS (both associated with ????
SBP) and COL21A1 (associated with PP). They had larger effect sizes than common variant ????
associations (>1.5mmHg per allele; Supplementary Figure 5) and were predicted to have ????
detrimental effects on protein structure (Supplementary Table 16; Methods). In RBM47, ????
rs35529250 (G538R) is located in a highly conserved region of the gene and was most ????
strongly associated with SBP (MAF=0.008; +1.59 mmHg per T allele; P=5.90x10-9). RBM47 ????
encodes the RNA binding motif protein 47 and is responsible for post-transcriptional ????
regulation of RNA, through its direct and selective binding with the molecule.33 In RRAS, ????
rs61760904 (D133N) was most strongly associated with SBP (MAF=0.007; +1.51 mmHg per ????
T allele; P=8.45x10-8). RRAS encodes a small GTPase belonging to the Ras subfamily of ????
proteins H-RAS, N-RAS, and K-RAS and has been implicated in actin cytoskeleton ????
remodelling, and controlling cell proliferation, migration and cycle processes 34. The nsSNV ????
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in COL21A1 (rs200999181, G655A) was most strongly associated with PP (MAF=0.001; ????
+3.14 mmHg per A allele; P=1.93x10-9). COL21A1 encodes the collagen alpha-1 chain ????
precursor of type XXI collagen, a member of the FACIT (fibril-associated collagens with an ????
interrupted triple helix) family of proteins 35. The gene is detected in many tissues, including ????
the heart and aorta. Based on our results, these three genes represent good candidates for ????
functional follow-up. However, due to the incomplete coverage of all SNVs across the region ????
on the Exome chip, it is possible that other non-genotyped SNVs may better explain some of ????
these associations. We therefore checked for variants in LD (r2>0.3) with these three rare ????
nsSNVs in the UK10K + 1000G dataset ?? to ascertain if there are other candidate SNVs at ????
these loci (Supplementary Table 17). There were no SNVs within 1Mb of the RBM47 locus ????
in LD with the BP associated SNV. At the COL21A1 locus there were only SNVs in ????
moderate LD, and these were annotated as intronic, intergenic or in the 5’UTR. At the RRAS ????
locus, there were two SNVs in strong LD with the BP associated SNV, which both mapped to ????
introns of the SCAF1 gene and are not predicted to be damaging. All SNVs in LD at both loci ????
were rare as expected (Supplementary Table 17) supporting a role for rare variants. Hence, ????
the rare BP associated nsSNVs at RBM47, COL21A1 and RRAS remain the best causal ????
candidates. ????
 ????
Pathway and network analyses ????
To identify connected gene sets and pathways implicated by the BP associated genes we used ????
Meta-Analysis Gene-set Enrichment of variant Associations (MAGENTA)37 and GeneGo ????
MetaCore (Thomson Reuters, UK).  MAGENTA tests for over-representation of BP ????
associated genes in pre-annotated pathways (gene sets) (Methods and Supplementary Table ????
18a). GeneGo Metacore identifies potential gene networks.  The MAGENTA analysis was ????
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used for hypothesis generation and results were compared with the GeneGo Metacore outputs ????
to cross-validate findings. ????
Using MAGENTA there was an enrichment (P<0.01 and FDR<5% in either the EUR_SAS ????
or the EUR participants) of six gene sets with DBP, three gene sets with HTN and two gene ????
sets for SBP (Supplementary Table 18b).  The RNA polymerase I promoter clearance ????
(chromatin modification) pathway showed the most evidence of enrichment with genes ????
associated with DBP (PReactome=8.4x10-5, FDR=2.48%). NOTCH signalling was the most ????
associated pathway with SBP (PReactome = 3.00x10-4, FDR = 5%) driven by associations at the ????
FURIN gene.  The inorganic cation anion solute carrier (SLC) transporter pathway had the ????
most evidence of enrichment by HTN associated genes (PReactome=8.00x10-6, FDR=2.13%).  ????
Using GeneGo MetaCore, five network processes were enriched (FDR<5%; Methods; ????
Supplementary Tables 19 and 20). These included several networks with genes known to ????
influence vascular tone and BP (inflammation signalling, P=1.14x10-4) and (blood vessel ????
development P=2.34x10-4). The transcription and chromatin modification network ????
(P=2.85x10-4) was also enriched, a pathway that was also highlighted in the MAGENTA ????
analysis, with overlap of the same histone genes (HIST1H4C, HIST12AC, HIST12BC, ????
HISTH1T) and has also been recently reported in an integrative network analysis of published ????
BP loci and whole blood expression profiling 38. Two cardiac development pathways were ????
enriched: the oxidative stress-driven (ROS/NADPH) (P=4.12x10-4) and the Wnt/β-????
catenin/integrin-driven (P=0.0010). Both these cardiac development pathways include the ????
MYH6, MYH7, and TBX2 genes, revealing a potential overlap with cardiomyopathies and ????
hypertension, and suggesting some similarity in the underlying biological mechanisms. ????
 ????
Discussion ????
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By conducting the largest ever genetic study of BP, we identified further novel common ????
variants with small effects on BP traits, similar to what has been observed for obesity and ????
height?????. More importantly, our study identified some of the first rare coding variants of ????
strong effect (>1.5mmHg) that are robustly associated with BP traits in the general ????
population, complementing and extending the previous discovery and characterisation of ????
variants underlying rare Mendelian disorders of blood pressure regulation ????Using SNV ????
associations in 17 genes reported to be associated with monogenic disorders of blood ????
pressure (Methods) we found no convincing evidence of enrichment (Penrichment = 0.044). This ????
suggests that BP control in the general population may occur through different pathways to ????
monogenic disorders of BP re-enforcing the importance of our study findings. The ????
identification of 30 novel BP loci plus further new independent secondary signals within four ????
novel and five known loci (Methods) has augmented the trait variance explained by 1.3%, ????
1.2% and 0.93% for SBP, DBP and PP respectively within our data-set. This suggests that ????
with substantially larger sample sizes, for example through UK BioBank?????we expect to ????
identify 1000s more loci associated with BP traits, and replicate more of our discovery SNV ????
associations that are not yet validated in the current report.  ????
The discovery of rare missense variants has implicated several interesting candidate genes, ????
which are often difficult to identify from common variant GWAS, and should therefore lead ????
to more rapidly actionable biology. A2ML1, COL21A1, RRAS and RBM47 all warrant further ????
follow-up studies to define the role of these genes in regulation of BP traits, as well as ????
functional studies to understand their mechanisms of action. COL21A1 and RRAS warrant ????
particular interest since both are involved in blood vessel remodelling, a pathway of known ????
aetiological relevance to hypertension.  ????
We observed a rare nonsense SBP associated variant in ENPEP (rs33966350; W317): this ????
overlaps a highly conserved region of both the gene and protein and is predicted to result in ????
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either a truncated protein with reduced catalytic function or is subject to nonsense mediated ????
RNA decay.  ENPEP converts angiotensin II (AngII) to Ang-III.  AngII activates the ????
angiotensin 1 (AT1) receptor resulting in vasoconstriction, while AngIII activates the ????
angiotensin 2 (AT2) receptor that promotes vasodilation and protects against hypertension.43 ????
The predicted truncated protein may lead to predominant AngII signaling in the body, and ????
increases in BP.  This new observation could potentially inform therapeutic strategies. Of ????
note, angiotensin-converting-enzyme (ACE) inhibitors are commonly used in the treatment of ????
hypertension. However, patients who suffer from adverse reactions to ACE inhibitors, such ????
as dry cough and skin rash, would benefit from alternative drugs that target RAAS. Murine ????
studies have shown that in the brain, AngIII is the preferred AT1 agonist that promotes ????
vasoconstriction and increases blood pressure, as opposed to AngII in the peripheral system. ????
These results have motivated the development of brain specific APA inhibitors to treat ????
hypertension44. Our results confirm APAs, such as ENPEP, as a valid target to modify blood ????
pressure, but suggest that long-term systemic reduction in APA activity may lead to an ????
increase in blood pressure. Future studies are needed to examine the effects of the W317X ????
variant on the RAAS system, specifically in the brain and peripheral vasculature, in order to ????
test the benefits of the proposed therapeutic strategy in humans.  ????
In addition to highlighting new genes in pathways of established relevance to BP and ????
hypertension, and identifying new pathways, we have also identified multiple signals at new ????
loci. For example there are three distinct signals at the locus containing the MYH6/MYH7 ????
genes, and we note that TBX2 maps to one of the novel regions. These genes are related to ????
cardiac development and/or cardiomyopathies, and provide an insight into the shared ????
inheritance of multiple complex traits. Unravelling the causal networks within these ????
polygenic pathways may provide opportunities for novel therapies to treat or prevent both ????
hypertension and cardiomyopathies. ????
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Overview of discovery studies ????
The cohorts contributing to the discovery meta-analyses comprise studies from three ????
consortia (CHD Exome+, ExomeBP, and GoT2D/T2D-GENES). The total number of unique ????
samples was 192,763.  All participants provided written informed consent and the studies ????
were approved by their local Research Ethics Committees and/or Institutional Review ????
Boards.  ????
 ????
The CHD Exome+ consortium included ten different collections (77,385 samples): eight ????
studies (49,898 samples) are of European (EUR) ancestry (EPIC-CVD, EPIC-InterAct, ????
CCHS, CGPS, CIHDS, PROSPER, MORGAM, WOSCOPS) and two studies (27,487 ????
samples) of South Asian ancestry (BRAVE, PROMIS). The ExomeBP consortium included ????
25 studies (75,620 samples) of EUR ancestry (Airwave, ASCOT, 1958BC, BRIGHT, ????
CROATIA_Korcula, DIABNORD, EGCUT, FENLAND, FINRISK97/02, GS:SFHS, ????
GLACIER, GoDARTS, GRAPHIC, HELIC-MANOLIS, HUNT, LBC1921, LBC1936, ????
LIFELINES, MDC, NFBC1986, OBB, PIVUS, TwinsUK, ULSAM, UKHLS).  The GoT2D ????
consortium comprised 14 studies (39,758 samples) of Northern EUR ancestry from Denmark ????
(ADDITION, HEALTH2006/2008, INTER99, SDC and Vejle Biobank), Finland (DPS, DR’s ????
EXTRA, FIN-D2D 2007, FINRISK 2007, FUSION, METSIM and PPP-Botania), and ????
Sweden (ANDIS and SDR). The participating studies and their characteristics, including ????
study design, BP ascertainment, measurement and exclusion criteria are detailed in ????
Supplementary Tables 1 and 2. Note, any studies contributing to multiple consortia were only ????
included once in all meta-analyses.  ????
Phenotypes ????
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Four blood pressure (BP) traits were analysed, these included three quantitative traits: ????
systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP); and one ????
binary outcome: hypertension (HTN).  For individuals known to be taking BP lowering ????
medication, 15 / 10 mmHg was added to the raw SBP / DBP values, respectively, to obtain ????
medication-adjusted SBP / DBP values 45.  PP was defined as the difference between SBP ????
and DBP, post-adjustment.  For the HTN phenotype, individuals were classified as ????
hypertensive cases if they satisfied at least one of the following criteria: (i) SBP ≥ 140 ????
mmHg, (ii) DBP ≥ 90 mmHg, (iii) taking anti-hypertensive or BP lowering medication.  All ????
other individuals were included within the hypertension analysis as controls. The four BP ????
traits are correlated (SBP:DBP correlations were between 0.6 and 0.8, and SBP:PP ????
correlations were approximately 0.8). However, they measure partly distinct physiological ????
features including, cardiac output, vascular resistance, and arterial stiffness, all measures for ????
determining a cardiovascular risk profile. Therefore the genetic architecture of the individual ????
phenotypes are of interest and a multi-phenotype mapping approach was not adopted. Details ????
of the BP phenotypes for each participating study are provided in Supplementary Table 1. ????
 ????
Genotyping ????
All samples were genotyped using one of the Illumina HumanExome Beadchip arrays ????
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design; Supplementary Table 3). ????
Genotyping was performed across the different studies using different arrays that contained ????
Exome chip SNVs and across several different sites (Supplementary Table 3). Most studies ????
followed comparable protocols for genotyping and quality control of resultant data. Full ????
details are given in Supplementary Information. All genotypes were aligned to the plus strand ????
of the human genome reference build 37 prior to any analyses and any unresolved mappings ????
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were removed. As an additional check, genotype cluster plots were reviewed for all the novel ????
rare variants (both lead and secondary signals) and for rare variants that contributed to the ????
gene-based testing to ensure good quality genotype calls. ????
 ????
Discovery SNV analyses ????
Two analyses of the continuous traits SBP, DBP, PP, were conducted within each ????
contributing study: inverse normal transformed and untransformed. The analyses of the ????
transformed traits were performed in order to minimise sensitivity to deviations from ????
normality in the analysis of rare variants, and hence were used for discovery of new SNV-BP ????
associations. The residuals from the null model obtained after regression of the medication-????
adjusted trait on the covariates (age, age2, sex, BMI, and disease status for CHD) within a ????
linear regression model, were ranked and inverse normalised. These normalised residuals ????
were used to test trait-SNV associations. All SNVs that passed QC were analysed for ????
association, without any further filtering by MAF, assuming an additive allelic effects model.?????
Full details of the analyses conducted within each study contributing to each of the consortia ????
are given in the Supplementary Information. ????
Two meta-analyses were performed for each trait, one with EUR only, and one with SAS and ????
EUR ancestries combined (EUR_SAS). We performed inverse variance weighted fixed effect ????
meta-analysis for continuous traits (SBP, DBP and PP) and sample size weighted meta-????
analysis for the binary trait (HTN) as implemented in METAL 46. Contributing studies used ????
PCs to adjust for population stratification, consequently minimal inflation in the association ????
test statistics, ?, was observed (?=1.07 for SBP, 1.10 for DBP, 1.04 for PP and <1 for HTN ????
in the transformed discovery meta-analysis in EUR_SAS; ?= 1.06 for SBP, 1.09 for DBP, ????
1.05 for PP and <1 for HTN in the transformed discovery meta-analysis in EUR; ????
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Supplementary Figure 6). We used I2 to calculate heterogeneity across studies ????
(Supplementary Figure 2). The meta-analyses were performed independently in two different ????
centres and concordance of results between the two centres was achieved following thorough ????
quality control checks. Given the studies contributing to the discovery analyses include ????
studies ascertained on CHD or T2D, we explored potential systematic bias in calculated ????
effect estimates amongst these studies. No evidence of bias in the overall effect estimates was ????
obtained. ????
The results for the transformed traits were taken forward and used to select candidate SNVs ????
for replication. Comparison of the results from the transformed and untransformed analyses ????
were made, and the correlations of association P-values across all SNVs on the Exome-chip ????
between the results were strong (r2> 0.9).  ????
Replication SNV analyses ????
We extracted SNVs associated with any of the transformed traits (SBP, DBP, PP) or HTN ????
and annotated them using the Illumina SNV annotation file - ‘humanexome-????
12v1_a_gene_annotation.txt’ independently across two sites. Given the difference in power ????
to detect common versus low frequency and rare variants, two different significance ????
thresholds were chosen for SNV selection. For SNVs with MAF ≥ 0.05, P ≤ 1x10-5, while, P ????
≤ 1x10-4 was used for SNVs with MAF < 0.05. By choosing a significance threshold of ????
P<1x10-4 we maximized the opportunity to follow-up rare variants (making the assumption ????
that any true signals at this threshold could replicate at Bonferroni adjusted significance, ????
P≤6.17x10-4, assuming α=0.05 for 81 SNVs). All previously published BP associated SNVs ????
and any variants in LD with them (r2 > 0.2), were removed from the list of associated SNVs ????
as we aimed to replicate new findings only. SNVs for which only one study contributed to the ????
association result or showed evidence of heterogeneity (Phet < 0.0001) were removed from ????
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the list as they were likely to be an artefact. Where SNVs were associated with multiple traits, ????
to minimise the number of tests performed, only the trait with the smallest P-value was ????
selected as the primary trait in which replication was sought. Where multiple SNVs fitted ????
these selection criteria for a single region, only the SNV with the smallest P-value was ????
selected. In total, 81 SNVs were selected for validation in independent samples. These 81 ????
SNVs had concordant association results for both transformed and non-transformed traits. ????
Eighty SNVs were selected from EUR_SAS and had consistent support in the EUR results, ????
and one variant in ZNF101 was selected based on support in EUR samples only. In the next ????
step, we looked up the 81 SNV-BP associations using data from a separate consortium, the ????
CHARGE+ consortium (who had analysed untransformed DBP, SBP, PP and HTN) and two ????
studies (UHP and Lolipop) from the ExomeBP consortium (Supplementary Information, ????
Supplementary Tables 2 and 3). The analysed residuals from CHARGE+ were approximately ????
normally distributed in their largest studies and plots of the untransformed distributions are ????
provided in Supplementary Figure 7? ????
Two meta-analyses of the replication datasets were performed: one in the EUR samples only, ????
and a second with EUR, African American, Hispanics and SAS ancestries (“ALL”). Both ????
used inverse variance weighted fixed effects meta-analysis (SBP/DBP/PP) and sample size ????
weighted meta-analysis (HTN) as implemented in METAL. Evidence of replication was only ????
confirmed if P (1-tailed) < 0.05/81=6.17x10-4 and the effect (beta) was in the direction ????
observed in our meta-analyses for the selected trait. A combined meta-analysis in METAL ????
was performed of discovery (untransformed results as only untransformed data was available ????
within the CHARGE+ consortium) and replication datasets across the four traits to assess the ????
overall support for each locus. For the combined meta-analyses, a GWS threshold of, ????
P≤5x10-8, was used to declare a SNV as novel rather than a less stringent experiment wide ????
threshold, as GWS is used to declare significance in GWAS and we wish to minimise the ????
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possibility of false positive associations. (Note that the GWS threshold of P ≤ 5x10-8 is also ????
equivalent to an exome-wide threshold of P≤2x10-7 adjusted for four traits). ????
 ????
Note: all final BP-associated variants that validated were associated at P<10-5 in the ????
discovery dataset (for the primary trait). Hence, we could have used the same inclusion ????
criteria for both common and rare SNVs. Therefore the optimal threshold to choose for future ????
experiments may need further consideration. ????
Conditional analyses and gene-based tests ????
The RAREMETALWORKER (RMW) tool ?? does not require individual level data to ????
perform conditional analyses and gene-based tests ????
(http://genome.sph.umich.edu/wiki/RAREMETALWORKER) and therefore was selected for ????
these analyses. All studies that contributed to the SNV discovery analyses were re-contacted ????
and asked to run the RMW tool. Within Exome BP consortium, only FENLAND, ????
GoDARTS, HELIC-MANOLIS, and UKHLS were unable to run RMW, while two new ????
studies were included, INCIPE and NFBC1966 (Supplementary Table 1 and 2).  Only EPIC-????
InterAct did not contribute to the RMW analyses from the CHD Exome+ consortium. All ????
studies were included from GoT2D. In total, 43 studies (147,402 samples) were included in ????
the EUR analyses and 45 studies (173,329 samples) in the EUR_SAS analyses. Further ????
details are provided in the Supplementary Information and Supplementary Tables 2 and 3.  ????
Comparison of the single variant discovery results with the new single variant results from ????
RMW, revealed very good correlation across the continuous BP traits (>0.77 in the ????
EUR_SAS and > 0.74 in the EUR only analyses). The differences were attributable to having ????
fewer samples and slightly different studies in the RMW dataset compared with the discovery ????
samples. ????
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For each novel locus, the genomic coordinates and size of the region were defined according ????
to recombination rates (Supplementary Table 9) around the lead variant. For known loci, a 1 ????
Mb window was used (Supplementary Table 14). Conditional analysis was performed across ????
each region, in both the EUR and EUR_SAS samples, for the transformed phenotype ????
corresponding to the validated BP trait for novel loci and the published BP trait for known ????
loci. ????
Gene based tests were performed with both the EUR and EUR_SAS datasets using the ????
Sequence Kernel Association Test (SKAT) ???within RMW as it allows for the SNVs to have ????
different directions and magnitudes of effect. Burden tests were also performed but are not ????
presented as only SKAT provided significant results. The variants in the gene-based tests ????
using SKAT were weighted using the default settings. Briefly, this used a beta distribution ????
density function to give more weight to rare variants, Beta(MAFj, 1, 25) where MAFj ????
represents the pooled MAF for variant j across all studies. Annotation of all variants with ????
information on genes and exon positions were derived from the UCSC reference file ????
"refFlat.txt.gz" (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/) and analyses ????
restricted to coding SNVs with MAF < 5% and MAF <1%. Association of genes with the ????
transformed DBP, SBP, PP traits and HTN were deemed to be associated if P <2.8x10-6 ????
(Bonferroni correction for 17,996 genes). To confirm the gene associations were not ????
attributable to a solitary SNV within the gene, a gene-based test conditional on the most ????
associated SNV was performed (Pconditional < 0.001). The QC of all SNVs contributing to the ????
gene based tests including the number of samples and studies contributing to the associations ????
were checked prior to claiming association. We also sought replication in the CHARGE+ ????
studies for any significant gene associations in the discovery analyses.  ????
 ????
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Pathway analyses ????
(1) Magenta ????
We tested seven databases in MAGENTA37 (BioCarta47, Kyoto Encyclopedia of Genes and ????
Genomes (KEGG)48, Ingenuity49, Panther50, Panther Biological Processes50, Panther ????
Molecular Functions 50 and Reactome ?????) for overrepresentation of the SNV discovery ????
results from both EUR and EUR_SAS ancestries. Each of the four BP phenotypes, HTN and ????
transformed DBP, SBP, and PP were tested.  MAGENTA maps SNVs to a gene based on ????
their chromosome and position. For SNVs not situated in a gene a ±20kb flanking region is ????
used to capture variants that potentially regulate that gene and the SNV with the smallest P-????
value is subsequently used to represent the gene. To adjust gene associations for potential ????
confounding, the model takes into account six possible predictors: (i) gene size (kb); (ii) ????
number of genotyped variants per kb; (iii) the number of independent variants per kb; (iv) the ????
number of recombination hotspots per kb; (v) the genetic distance (cM) per kb; and (vi) the ????
LD units per kb. The proportion of genes that have an adjusted P-value less than the 95th ????
percentile of the gene P-value meta-analysis distribution is the “leading edge fraction”. The ????
enrichment P-value for a pathway is the proportion of random pathways of identical size, in ????
10,000 permutations, whose leading edge fraction is greater than or equal to the observed ????
leading edge fraction. Pathways exhibiting P<0.01 and FDR<5% were considered ????
statistically significant. ????
(2) GeneGo MetaCore Network analyses ????
A set of BP genes based on previously published studies and our current Exome chip results ?????
(locus defined as r2 > 0.4 and 500kb on either side of tag SNV; Supplementary Table 19) was ?????
tested for enrichment using the THOMSON REUTERS MetaCoreTM Single Experiment ?????
Analysis workflow tool. The manually uploaded data set was mapped onto selected ?????
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MetaCore ontology databases such as: pathway maps, process networks, GO processes and ?????
diseases / biomarkers, for which functional information is derived from experimental ?????
literature. Outputs were sorted based on the P- and FDR-values. Stringent thresholds were ?????
adopted for determining whether the given gene set was enriched for a particular process ?????
(P<0.05, FDR<5%). ?????
 ?????
Genetic Risk Score ?????
 ?????
To assess the effect of BP on CHD, ischemic stroke (and three of its subtypes: large vessel, ?????
small vessel and cardioembolic stroke) left ventricular mass, left ventricular wall thickness, ?????
heart failure, HDL-c, LDL-c, total cholesterol, triglycerides and eGFR, we performed a ?????
weighted generalized linear regression of the genetic associations with each outcome variable ?????
on the genetic associations with BP accounting for the correlations between genetic variants.  ?????
When genetic variants are uncorrelated, the estimates from such a weighted linear regression ?????
analysis using summarized data, and a genetic risk score analysis using individual-level data, ?????
are equal 53. We refer to the analysis as a genetic risk score (also known as a polygenic risk ?????
score) analysis as this is likely to be more familiar to applied readers. As some of the genetic ?????
variants in our analysis are correlated, a generalized weighted linear regression model is fitted ?????
that accounts for the correlations between variants. This is undertaken as follows:  ?????
If ?? are the genetic associations (beta-coefficients) with the risk factor (here, BP) and ?? are ?????
the genetic associations with the outcome, then the causal estimate from a weighted ?????
generalized linear regression is ????????????????????, and the standard error is ?????
? ????????????, where T is a matrix transpose, ? is the estimate of the residual standard ?????
error from the regression model, and the weighting matrix ? has terms ????? ? ?????????????, ?????
where ??? is the standard error of the genetic association with the outcome for the jth SNV, ?????
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and ????? is the correlation between the j1th and j2th SNPs. The presence of the estimated ?????
residual standard error allows for heterogeneity between the causal estimates from the ?????
individual SNVs as overdispersion in the regression model (in the case of underdispersion, ?????
the residual standard error estimate is set to unity). This is equivalent to combining the causal ?????
estimates from each SNV using a multiplicative random-effects model ??? ?????
 ?????
For each of DBP, SBP and PP, the score was created using both the novel and known BP ?????
SNVs or a close proxy (r2>0.8). Both the sentinel SNV association and any secondary SNV ?????
associations that remained after adjusting for the sentinel SNV were included in the genetic ?????
risk score. For the 30 validated novel SNV-BP associations, βs were taken from the ?????
independent replication analyses (Table 1a and 1b) to weight the SNV in the genetic risk ?????
score. For the secondary SNVs from the novel loci (N=7) and known loci (N=5), βs were ?????
taken from the discovery analyses (Supplementary Tables 10 and 15). For the 82 published ?????
known SNVs, 43 SNVs were either genotyped or had proxies on the Exome chip and the βs ?????
were taken from discovery results (Supplementary Table 13), the remaining βs were taken ?????
from published effect estimates. This strategy for selecting betas for use in the GRS was ?????
taken to minimize the influence of winners curse. The associations between the BP variants ?????
with CHD, HDL-c, LDL-c, total cholesterol, log(triglycerides) and log(eGFR) were obtained ?????
using the CHD Exome+ Consortium studies (N=82,056, N=80,395, N=77,021, N=80,455, ?????
N= 77,779 and N=51,039 respectively) the associations with BMI, waist-hip ratio adjusted ?????
BMI and height were obtained from the GIANT consortium (unpublished Exome chip ?????
results, N=526,508, 344,369 and 458,927 respectively) and for ischemic stroke, left ?????
ventricular mass, left ventricular wall thickness and heart failure (N= 25,799, N= 11,273, ?????
N=11,311, and N=?23,821) from METASTROKE ??, EchoGen ?? and CHARGE-HF ??. A ?????
causal interpretation of the association of GRS with the outcome as the effect of BP on the ?????
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outcome assumes that the effects of genetic variants on the outcome are mediated via blood ?????
pressure and not via alternate causal pathways, for example via LV thickness. There are also ?????
limitations of the Mendelian randomization approach in distinguishing between the causal ?????
effects of different measures of blood pressure, due to the paucity of genetic variants ?????
associated with only one measure of blood pressure (for example, SBP, DBP or PP). ?????
 ?????
eQTL analyses ?????
The MuTHER dataset contains gene expression data from 850 UK twins for 23,596 probes ?????
and 2,029,988 (HapMap 2 imputed) SNVs. All cis–associated SNVs with FDR<1%, within ?????
each of the 30 novel regions (IMPUTE info score >0.8) were extracted from the MuTHER ?????
project dataset for each of the tissues, LCL (n=777), adipose (n=776) and skin (n=667) ??. ?????
The pilot phase of the GTEx Project (dbGaP Accession phs000424.v3.p1)?provides ?????
expression data from up to 156 individuals for 52,576 genes annotated in Gencode v12 ?????
(including pseudo genes) and 6,820,472 genotyped SNVs (using the Human Omni5-Quad ?????
array) and imputed SNVS (to the 1000 Genomes project reference post-QC, info > 0.4, MAF ?????
> 5%) ??.  The eQTL analysis was focused on nine tissues having more than 80 samples and ?????
genes expressed at least 0.1 RPKM in 10 or more individuals in a given tissue. All transcripts ?????
with a transcription start site (TSS) within one of the 30 new BP loci and for which there was ?????
a cis-associated SNV (IMPUTE info score > 0.4) within 1Mb of the TSS at FDR<5%, were ?????
identified. Data were extracted for: subcutaneous adipose tissue (n=94), tibial artery (n=112), ?????
heart (left ventricle) (n=83), lung (n=119), skeletal muscle (n=138), tibial nerve (n=88), skin ?????
(sun exposed, lower leg) (n=96), thyroid (n=105) and whole blood (n=156). We were not able ?????
to evaluate presence of expression signals in kidney tissue, since the currently available ?????
sample size in GTEx (n=8) is too small to enable calculation of eQTLs. Only data for SNVs ?????
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with MAF > 0.05 were considered. From each resource, we report eQTL signals, which reach ?????
the resource-specific thresholds for significance described above, for SNVs that are in LD ?????
(r2>0.8) with our sentinel SNV. ?????
For identified eQTLs, we tested whether they colocalised with the BP associated SNV using ?????
a Bayesian approach based on summary statistics ??. Colocalisation analyses were considered ?????
to be significant if the posterior probability of colocalisation was greater than 0.95. ?????
Annotation of variants and literature review ?????
In silico prediction of the functional effect of detected variants was based on the annotation ?????
from the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/), the Ensembl Variant Effect ?????
Predictor (VEP) tool (http://www.ensembl.org/info/docs/tools/index.html) and from the ?????
Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA ?????
(http://evs.gs.washington.edu/EVS/) on March 2015 and February 2016. Annotation was ?????
performed for each known Ensembl transcript or regulatory feature regardless of the biotype. ?????
Information about the effect on transcript and protein level, including various effect ?????
prediction scores (PolyPhen, SIFT, Grantham), evolutionary conservations scores ?????
(phastCons, GERP) and variant frequency in various populations (AFR, AMR, ASN, EAS, ?????
EUR, SAS), was collected. Details of the literature review are provided in the Supplementary ?????
Information. ?????
Trait variance explained ?????
The percentage trait variance explained for SBP, DBP, PP was assessed with 5,861 ?????
individuals from a population-based cohort (1958BC) with complete information for all ?????
phenotypes and covariates.   ?????
38
Two different genetic models were investigated: one containing the 43 previously known BP ?????
associated SNVs covered on the Exome chip, as a baseline reference; and a second model ?????
additionally including the 30 novel lead SNVs and 9 of the new independent additional SNVs ?????
from both novel and known loci with multiple signals, giving a total of 82 known and novel ?????
SNV predictors.  These 9 additional new independent SNVs were taken as the secondary ?????
signals identified within the novel and known loci from the conditional analyses of the EUR ?????
dataset, as 1958BC contains European subjects only. Hence the 9 independent variants ?????
included: 4 secondary variants from novel loci for EUR (PREX1, COL21A1, PRKAG1 and ?????
MYH6 (there was only 1 in EUR) loci; Supplementary Table 10) and 5 secondary variants ?????
from known loci for EUR (ST7L-CAPZA1-MOV10, FIGN-GRB14, ENPEP, TBX5-TBX3 and ?????
HOXC4; Supplementary Table 15). ?????
The residual trait was obtained by adjusting each of the medication-adjusted BP traits with ?????
sex and BMI variables, the same covariates used within the discovery SNV analyses (not age ?????
or age2 as all 1958BC individuals were aged 44 years).  A linear regression was fitted for the ?????
residual trait regressed on all SNVs within the corresponding model and adjusted for the first ?????
ten principal components (PCs).  The r2 calculated from this regression model was used as the ?????
percentage trait variance explained.  The comparison of r2 measures between the 43-SNV ?????
model and the 82-SNV model was used to indicate the incremental increase in percentage ?????
trait variance explained due to all the novel SNVs identified. ?????
 ?????
Monogenic Enrichment analyses ?????
To determine if sub-significant signals of association were present in a set of genes associated ?????
with monogenic forms of disease, we performed an enrichment analysis of the discovery ?????
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single variant meta-analysis association results for all four traits for both for individuals of ?????
EUR ancestry and EUR_SAS ancestry datasets. ?????
The monogenic gene set included: WNK1, WNK4, KLHL3, CUL3, PPARG, NR3C2, ?????
CYP11B1, CYP11B2, CYP17A1, HSD11B2, SCNN1A, SCNN1B, SCNN1G, CLCNKB, ?????
KCNJ1, SLC12A1, SLC12A3 ?.  The association results of coding SNVs in these genes were ?????
extracted and the number of tests with P<0.001 observed.  In order to determine how often ?????
such an observation would be observed by chance, we constructed 1,000 matched gene sets. ?????
The matching criteria for each monogenic gene was the intersection of all genes in the same ?????
exon length quintile and all genes in the same coding variant count decile. Within the ?????
matched sets, the number of variants with P<0.001 was observed.  The empirical P-value was ?????
calculated as the fraction of matched sets with an equal or larger number of variants less than ?????
0.001. ?????
 ?????
  ?????
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Table 1a. Novel blood pressure trait associated loci. Variants with formal replication  
 
Variant information  Discovery Replication Combined 
Locus rsID Chr:Pos (EA:EAF) Trait Pt PU N β P N β P 
EUR 
RNF207 rs709209 1:6.28 (A:0.655) PP 4.57x10-6 1.60x10-6 122780 0.17 5.83x10-4 284683 0.20 9.62x10-9 
c5orf56 rs12521868 5:131.78 (T:0.373) DBP 1.59x10-6 3.03x10-7 122795 -0.18 2.29x10-5 282023 -0.19 6.12x10-11 
PHACTR1 rs9349379 6:12.90 (A:0.566) SBP 2.11x10-8 1.78x10-7 122809 0.24 4.06x10-4 284673 0.29 8.84x10-10 
COL21A1 rs200999181† 6:55.94 (A:0.002) PP 3.08x10-8 2.46x10-7 121487 2.70 1.90x10-4 242486 3.25 6.27x10-10 
ABO rs687621 9:136.14 (A:0.615) DBP 8.80x10-8 2.55x10-7 122798 0.16 1.96x10-4 276014 0.19 5.45x10-10 
ADO rs10995311 10:64.56 (C:0.567) DBP 1.86x10-6 1.14x10-6 122798 0.23 8.47x10-8 266456 0.21 1.12x10-12 
LMO1 rs110419 11:8.25 (A:0.48) DBP 9.41x10-6 2.22x10-5 122798 0.16 1.81x10-4 279935 0.16 3.04x10-8 
OR5B12 rs11229457 11:58.21 (T:0.236) SBP 1.58x10-6 4.62x10-5 122809 -0.32 7.53x10-5 284680 -0.31 2.70x10-8 
CERS5 rs7302981 12:50.54 (A:0.361) DBP 1.35x10-13 4.60x10-11 122798 0.24 2.64x10-8 284718 0.25 1.38x10-17 
MYH6 rs452036 14:23.87 (A:0.327) PP 4.59x10-11 2.80x10-13 122780 -0.21 1.81x10-5 284672 -0.28 2.96x10-16 
DPEP1 rs1126464 16:89.70 (C:0.256) DBP 1.19x10-9 4.35x10-11 118677 0.24 1.68x10-6 261564 0.28 1.02x10-15 
TBX2 rs8068318† 17:59.48 (T:0.698) DBP 7.46x10-13 5.71x10-10 122798 0.26 3.23x10-8 281978 0.26 1.95x10-16 
RGL3 rs167479 19:11.53 (T:0.486) DBP 2.22x10-23 1.97x10-22 122797 -0.29 3.01x10-11 283332 -0.33 1.99x10-31 
PREX1 rs6095241 20:47.31 (A:0.452) DBP 5.65x10-6 2.29x10-5 122798 -0.18 2.56x10-5 281322 -0.17 4.75x10-9 
ALL ancestry 
RBM47 rs35529250† 4:40.43 (T:0.01) SBP 6.56x10-7 6.15x10-6 148878 -1.43 5.02x10-4 306352 -1.55 2.42x10-8 
OBFC1 rs4387287 10:105.68 (A:0.157) SBP 2.23x10-8 1.32x10-7 147791 0.28 3.37x10-4 320494 0.36 9.12x10-10 
RRAS rs61760904† 19:50.14 (T:0.008) SBP 1.96x10-6 1.90x10-5 148878 1.38 5.70x10-4 322664 1.50 8.45x10-8 
SNV-BP associations are reported for the newly identified BP loci that replicated at P<6.2x10-4 (Bonferroni correction for the 81 variants selected for replication for a primary blood 
pressure trait; Methods). Loci are categorised into EUR and ALL ancestry based on the meta-analysis used to replicate the variants for the primary BP trait shown in column 
labelled ‘Trait’. In the columns that contains  the discovery meta-analyses results, Pt represents the P-value for association of the variant with the transformed primary BP trait in 
the EUR_SAS discovery meta-analyses (which was also used to select the variant for replication) and Pu  represents the P-value for association with the untransformed primary BP 
trait in the ancestry in which the variant replicated. N, β and P, denotes the number of samples, estimated allelic effect and P-value for association with the primary BP trait, are 
provided for the untransformed primary BP trait in the replication data and also from the combined (discovery and replication) meta-analyses. NB: ALL ancestry corresponds to all 
ancestries in the combined (discovery + replication) meta-analyses 
Locus – Gene or region containing the SNV, rsID - dbSNP rsID. Chr:Pos (EA:EAF) – Chromosome:NCBI Build 37 position in Mb (effect allele:effect allele frequency), Trait – 
primary blood pressure trait for which the variant was and also replicated, β - effect estimate, N:sample size, EUR - European.  
† indicates it is a non-synonymous SNV (nsSNV) or is linkage disequilibrium with a nsSNV (r2>0.8) that is predicted to be damaging  
  ?
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Table 1b. Novel blood pressure trait associated loci. Variants with GWS evidence of association in combined 
meta-analyses 
 
Variant information  Discovery Replication Combined 
Locus rsID Chr:Pos (EA:EAF) Trait Pt PU N β P N β P 
EUR 
2q36.3 rs2972146 2:227.10 (T:0.652) DBP§ 
(HTN) 
1.51x10-9 2.47x10-7 122798 0.13 2.20x10-3 275610 0.17 8.40x10-9 
ZBTB38 rs16851397 3:141.13 (A:0.953) DBP§ 
(SBP) 
6.87x10-6 3.20x10-5 122798 -0.38 1.20x10-4 284717 -0.38 3.01x10-8 
PRDM6 rs1008058 5:122.44 (A:0.135) SBP 5.09X10-7 1.01x10-8 43109 0.46 3.61x10-3 176362 0.55 2.99x10-10 
GPR20 rs34591516 8:142.37 (T:0.055) SBP§ 
(DBP) 
1.54x10-6 1.01x10-7 122807 0.51 4.20x10-4 282009 0.64 6.10x10-10 
HOXB7 rs7406910 17:46.69 (T:0.118) SBP 6.07X10-10 2.74x10-9 122809 -0.20 4.89x10-2 284690 -0.46 3.80x10-8 
AMH rs10407022† 19:2.25 (T:0.82) PP 1.63X10-7 1.73x10-7 118656 -0.19 1.62x10-3 252525 -0.26 5.94x10-9 
ZNF101 rs2304130 19:19.79 (A:0.914) DBP 1.66X10-8 1.92x10-8 122798 -0.17 1.71x10-2 284705 -0.29 1.53x10-8 
PROCR rs867186 20:33.76 (A:0.873) DBP 1.44X10-6 4.15x10-7 122798 0.21 2.48x10-3 284722 0.26 1.19x10-8 
RRP1B rs9306160 21:45.11 (T:0.374) DBP§ 
(SBP) 
1.04x10-8 1.90x10-6 100489 -0.16 4.30x10-4 249817 -0.18 6.80x10-9 
TNRC6B rs470113 22:40.73 (A:0.804) PP 1.48X10-10 1.31x10-9 122780 -0.14 1.37x10-2 284683 -0.25 1.67x10-9 
ALL ancestry 
7q32.1 rs4728142 7:128.57 (A:0.433) SBP 8.10x10-6 4.21x10-6 150542 -0.21 8.62x10-4 338338 -0.24 3.45x10-8 
PRKAG1 rs1126930† 12:49.40 (C:0.036) PP 2.12x10-6 4.62x10-7 151481 0.36 3.74x10-3 314894 0.50 3.34x10-8 
SBNO1 rs1060105 12:123.81 (T:0.209) DBP 6.66x10-7 1.09x10-6 150532 -0.15 2.67x10-3 336413 -0.18 3.07x10-8 
 
SNV-BP associations are reported for the newly identified BP loci that showed genome-wide significant association (P<5x10-8) in the combined discovery and replication meta-
analyses. In the columns that contain results from the discovery meta-analyses, Pt represents the P-value for association of the variant with the transformed primary BP trait in the 
EUR_SAS discovery meta-analyses (used to select the variant for replication) and Pu represents the P-value for association with the untransformed BP trait in the ancestry in which 
the variant was validated.  For four loci (2q36.3, ZBTB38, GPR20 and RRP1B) Pt  denotes the association P-value with the primary trait, which is given in parentheses, however, 
the locus was validated for a secondary trait, which is listed. Loci are categorised into EUR and ALL ancestry based on the ancestry in which the variant showed association with a 
blood pressure trait at P<5x10-8. N, β and P, denotes the number of samples, estimated allelic effect and P-value for association with the validated BP trait, are provided for the 
untransformed BP trait in the replication data and also from the combined (discovery and replication) meta-analyses. NB: ALL ancestry corresponds to all ancestries in the 
combined (discovery + replication) meta-analyses.  
 
Locus – Gene or region containing the SNV, rsID - dbSNP rsID. Chr:Pos (EA:EAF) – Chromosome:NCBI Build 37 position in Mb (effect allele:effect allele frequency), Trait - blood 
pressure trait for which association is reported, EUR - European.  
§ indicates the trait with which the variant showed the strongest association in the combined meta-analyses. For variants where this trait is different from the primary phenotype, 
the primary BP trait used to select the variants is shown in the parantheses 
† indicates it is a non-synonymous SNV (nsSNV) or is linkage disequilibrium with a nsSNV (r2>0.8) that is predicted to be damaging 
  ?
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Table 2 Gene-based associations with BP traits from the SKAT model ?
 ?
 
Gene 
 
Chr:Start-End 
 
n_var 
 
Trait MAFc MAFmin MAFmax P Pcond 
EUR (Novel) 
       
A2ML1 12:8.975-9.03 51 HTN 0.01 3.43x10-6 0.0077 2.36x10-6 9.17x10-4 
EUR_SAS (Novel)        
A2ML1 12:8.975-9.03 54 HTN 0.01 2.91x10-6 0.0067 6.83x10-7 5.00x10-4 
 
Novel blood pressure associated gene with P<2.8x10-6 (Bonferroni corrected P-value for the 17,996 genes tested) from the RareMetalWorker (RMW) SKAT 
test are given. Results are shown from both the EUR and EUR_SAS ancestry datasets. There was no evidence of association of this gene with HTN in the 
CHARGE+ studies used for replication (P= 0.45).  
Chr:Start-End – Chromosome: GRCh37 start and end bp coordinates of the Gene in Mb, n_var - number of exonic variants tested., Trait – HTN 
(Hypertension) or transformed primary quantitative blood pressure trait, MAFc - minor allele frequency filter applied to select variants for the test, MAFmin - 
minimum MAF of variants tested, MAFmax - maximum MAF of variants tested, P - P-value for association of the gene with the trait, Pcond - P-value for 
association of gene with the phenotype conditioned on the exonic variant that had the smallest association P-value with the phenotype in the single variant 
association RMW meta-analysis.  
  
 ?
 ?
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Table 3 Results of the genetic risk score analyses across CVD traits and risk factors. ?
??
??
Outcome Units N DBP (per 10mmHg increase) SBP (per 10mmHg increase) PP (per 10mmHg increase) 
   Effect [95% CI] P Effect [95% CI] P Effect [95% CI] P 
CHD OR 82,056  1.62 [ 1.28, 2.05] 5.99x10-5  1.39 [ 1.22, 1.59] 6.07x10-7  1.70 [ 1.34, 2.16] 1.20x10-5 
Ischemic stroke OR 25,799  1.93 [ 1.47, 2.55] 2.81x10-6  1.57 [ 1.35, 1.84] 1.16x10-8  2.12 [ 1.58, 2.84] 5.35x10-7 
Cardioembolic stroke OR 16,113  1.43 [ 0.86, 2.39] 0.1683  1.33 [ 0.99, 1.80] 0.0584  1.73 [ 1.00, 3.02] 0.0518 
Large vessel stroke OR 13,903  2.26 [ 1.25, 4.08] 0.0068  1.85 [ 1.32, 2.59] 3.61x10-4  3.05 [ 1.64, 5.68] 4.37x10-4 
Small vessel stroke OR 15,617  1.96 [ 1.13, 3.41] 0.0168  1.56 [ 1.13, 2.16] 0.0064  1.98 [ 1.09, 3.61] 0.0248 
Heart failure OR 13,282  1.48 [ 1.02, 2.17] 0.0409  1.25 [ 1.00, 1.57] 0.0512  1.33 [ 0.88, 2.02] 0.1757 
Left ventricular mass g 11,273  9.57 [ 3.98,15.17] 8.02x10-4  5.13 [ 1.77, 8.48] 0.0027  5.97 [-0.38,12.31] 0.0653 
Left ventricular wall thickness cm 11,311  0.10 [ 0.06, 0.13] 1.88x10-8  0.05 [ 0.03, 0.07] 5.52x10-6  0.05 [ 0.01, 0.09] 0.0187 
HDL mg/dl 80,395  0.25 [-1.00, 1.51] 0.6930  0.21 [-0.50, 0.92] 0.5622  0.47 [-0.79, 1.73] 0.4668 
LDL mg/dl 77,021 -1.57 [-5.20, 2.06] 0.3972  0.07 [-2.03, 2.16] 0.9498  1.87 [-1.86, 5.59] 0.3255 
Total cholesterol mg/dl 80,455 -1.34 [-5.90, 3.22] 0.5639  0.70 [-1.93, 3.32] 0.6029  3.68 [-0.97, 8.33] 0.1209 
Triglycerides mg/dl 77,779  0.02 [-0.03, 0.08] 0.3859  0.02 [-0.01, 0.05] 0.2697  0.03 [-0.03, 0.08] 0.3025 
BMI INVT 526,508 -0.10 [-0.18,-0.01] 0.0342 -0.07 [-0.13,-0.02] 0.0058 -0.12 [-0.23,-0.02] 0.0165 
WHRadjBMI INVT 344,369  0.03 [-0.04, 0.11] 0.4025  0.03 [-0.02, 0.08] 0.2170  0.06 [-0.03, 0.15] 0.1885 
Height INVT 458,927  0.02 [-0.15, 0.18] 0.8592 -0.04 [-0.15, 0.06] 0.4170 -0.18 [-0.37, 0.01] 0.0683 
eGFR INVT 51,039 -0.02 [-0.15, 0.11] 0.7810 -0.03 [-0.10, 0.04] 0.4080 -0.07 [-0.20, 0.06] 0.2741 
CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; DBP, diastolic blood pressure; SBP systolic blood pressure; PP, pulse pressure; OR, odds ratio; g, grams; INVT, inverse norma
transformed (hence no units); N, sample size; P, P-value of association of BP with the trait listed; CI, confidence interval. Results are considered significant if P < 0.0038, which corresponds to a Bonferroni correction for 13 phenotypes tested. 
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Figure 1 Study design and work flow diagram of single variant discovery analyses.  ?
?
? ?
EUR=European, SAS=South Asian, HIS=Hispanic, AA=African American, HTN=hypertension, BP=blood pressure, SBP=systolic blood pressure, DBP= diastolic blood pressure, ?
PP=pulse pressure, N=sample size, MAF=minor allele frequency, P=P-value significance threshold, SNV=single-nucleotide variant, GWS=genome-wide significance *Further details ?
of the selection criteria are provided in the methods. ?
 ?
 ?
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Figure 2 Discovery SNV-BP associations.  Results are provided for (a) transformed SBP (b) transformed DBP (c) ?
transformed PP and (d) HTN in the European and South Asian (EUR_SAS) discovery samples. The y-axis represents –?
log10P for association. Red triangles represent variants that map to one of the 81 regions selected for replication, blue ?
triangles represent SNVs that map to previously published BP regions, and grey triangles represent all remaining SNVs. ?
SNVs are ordered according to chromosome (black lines on the outside of the plot) and physical position. Genes that ?
SNVs map to are given in the outer lilac blocks. ?
 ?
 ?
 ?
 ?
????
???? ??? ????????
?? ?? ?????????
? ??? ??
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Figure 3 Overlap of the 30 novel loci associations across SBP, DBP, PP and HTN.  ?
??
The Venn diagram shows which of the 30 newly identified BP loci are associated with multiple BP traits. Only SNV-BP trait associations that were genome-wide significant (P < ?
5x10-8) in the combined discovery and replication meta-analyses are listed for any given BP trait, within the corresponding ancestry dataset that the given locus was validated for ?
(see Tables 1a and 1b). The association of RRAS variant with SBP was replicated in the independent samples, but did not achieve GWS in the combined discovery and replication ?
meta-analysis and is therefore only included for SBP. HTN=hypertension, SBP=systolic blood pressure, DBP= diastolic blood pressure, PP=pulse pressure. ?
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Figure 4 Study design for conditional analyses and rare variant gene-based discovery analyses.  ?
?  ?
RMW=RareMetalWorker, EUR=European, SAS = South Asian, HTN=hypertension, BP=blood pressure, SBP=systolic blood pressure, DBP= diastolic blood pressure, PP=pulse pressure. N=sample size, MAF=minor allele frequency, P=P-value significance ?
threshold, Pcond=conditional P-value significance threshold??
??
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Figure 5 Locus plot for A2ML1 and secondary amino acid structure of the gene product.  ?
(a) Locus plot for A2ML1 associated with HTN identified through gene based tests. The variants’ positions along the ?
gene (x axis, based on human genome build 37) and the –log10(P-value of association) (y axis) are indicated. The ?
variants are colour coded: nonsense (blue), missense, predicted damaging (green), and missense (red). The schematic ?
above the x-axis represents the intron / exon (black vertical bars) structure, the untranslated regions are shown as grey ?
vertical bars. ?
?b) The white box denotes the full-length amino acid sequence for each of the two gene products. Black numbers ?
denote amino acid residue positions of note. Coloured boxes depict putative functional domains (see below). Coloured ?
vertical lines indicate the amino acid substitutions corresponding to the variants depicted in the locus plots above using ?
the same colour coding. Bold, italic indicates the SNV association with smallest P-value. ?
Dark grey – signal peptide sequence. Brown – regions of intramolecular disulfide bonds. For simplicity only those ?
regions coinciding with variants described were indicated. Black – bait region described to interact with proteases. ?
Purple – thiol ester sequence region aiding in interaction with proteases. Light grey – alpha helical regions thought to ?
mediate A2ML1 interaction with LRP1, facilitating receptor-mediated endocytosis. ?
 ?
 ?
 ?
 ?
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